Recent research has revealed that the product of the von Hippel–Lindau (VHL) tumor suppressor gene, which is deactivated in VHL disease and sporadic clear cell renal carcinomas, targets the transcription elongation complex known as elongin. This evidence concerns the gene VHL and von Hippel-Lindau disease.